The board of directors of Everest Medicines Limited announced that Mr. Yubo Gong ("Mr. Gong'') has resigned as a non-executive director of the Company with effect from 9 February 2024 to devote more time to his other business endeavours. Mr. Gong has confirmed that he has no disagreement with the Board and that there are no matters that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the ?Stock Exchange'') relating to his resignation. The Board announces that Mr. Honggang Feng ("Mr. Feng'') has been appointed as a non- executive director of the Company with effect from 9 February 2024.

Mr. Feng, aged 59, has more than 35 years of experience in the healthcare industry. He is currently a senior advisor of CBC Group, a controlling shareholder of the Company, where he assists in portfolio management and is responsible for the post-investment management. He was the president of Simcere Pharmaceutical Group Limited from January 2015 to November 2019, and held other leadership positions in Simcere from 1994 to 2007, including as a director of biomedical department, vice president of its research institute and as a director of marketing department.

From August 2007 to October 2014, Mr. Feng was the general manager of Shihuida Pharma Group. Mr. Feng started his career as an internist and an endocrinologist in different hospitals. Mr. Feng received his medical education from Yangzhou Medical College (now known as Medical School, Yangzhou University) in 1982 and obtained a Master of Medicine from China Medical University in 1989.